The EDC3 Knockout HEK293T Polyclonal Cells are a polyclonal population of HEK293T cells with CRISPR/Cas9-mediated disruption of the EDC3 gene. This loss-of-function model enables investigation of EDC3’s role in mRNA decapping and post-transcriptional gene regulation. The polyclonal format provides a heterogeneous pool of gene-edited cells, suitable for bulk functional studies without clonal isolation. These cells serve as a versatile tool for studying pathways involving the DCP1-DCP2 decapping complex and P-body dynamics.
HEK293T cells are a widely utilized human embryonic kidney epithelial cell line that constitutively expresses the SV40 large T antigen. This feature supports high-copy episomal replication of plasmids containing the SV40 origin of replication, making the line ideal for transient and stable transfection, protein overexpression, and lentiviral/retroviral production. The robust growth characteristics and ease of genetic manipulation of HEK293T cells make them a preferred host for generating knockout models to study gene function in a readily transfectable background.
EDC3 functions as a scaffold enhancer of the DCP1-DCP2 mRNA decapping holoenzyme, directly interacting with DCP1A, DCP2, and the LSm1-7 complex to stimulate 5′ cap removal. This activity initiates 5′-to-3′ mRNA degradation by the exonuclease XRN1, controlling the stability of transcripts including nonsense-mediated decay substrates and microRNA-targeted mRNAs. EDC3 is a core component of processing bodies, where it helps concentrate decapping machinery. Its function is regulated by upstream kinases such as AKT and mTORC1, which respond to growth factor signaling and oxidative stress, thus linking mRNA decay to cellular metabolic status.
Disruption of EDC3 in HEK293T cells provides a tractable system to dissect the molecular requirements for decapping activation and P-body assembly in a non-neuronal context. Since HEK293T supports robust expression of heterologous genes, this knockout model facilitates rescue and structure-function studies to map EDC3 domains critical for interaction with DCP1A, DDX6, and the LSm1-7 complex. Given that EDC3 has been implicated in intellectual disability and cancer, this cellular model offers a scalable platform to interrogate the mechanistic basis of decapping-dependent mRNA regulation and to screen for modulators of the decapping pathway.
Researchers can employ these EDC3-knockout polyclonal cells in a variety of experimental workflows, including actinomycin D chase assays to measure mRNA half-life changes by RT-qPCR or RNA-seq, immunofluorescence staining of P-body markers such as DCP1A and EDC4 to assess granule dynamics under stress conditions, and co-immunoprecipitation to probe decapping complex integrity. The model is also suited for luciferase-based mRNA decay reporters, polysome profiling to examine translational impacts, and drug testing of novel decapping inhibitors. In particular, comparing wild-type HEK293T with the EDC3-knockout population allows delineation of EDC3-dependent versus -independent decay pathways, facilitating target validation for diseases linked to aberrant mRNA stability. For further details, please contact Ascent Research.
